Dr. Howard Fillit is a renowned geriatrician, neuroscientist, and expert in Alzheimer’s disease research and treatment. He is the founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF), a leading nonprofit organization dedicated to accelerating the discovery and development of drugs to prevent, treat, and cure Alzheimer’s disease. Under his leadership, the ADDF has provided critical funding for over 700 drug discovery programs and early-stage clinical trials, helping to advance innovative therapeutic approaches for Alzheimer's and other age-related dementias.

With a career spanning over 30 years, Dr. Fillit has made significant contributions to the fields of aging and neurodegeneration, combining his expertise in clinical practice with groundbreaking research. He has authored more than 350 publications and has served as a professor of Geriatrics, Medicine, and Neuroscience at the Icahn School of Medicine at Mount Sinai in New York. Dr. Fillit's unique approach focuses on the intersection of aging and Alzheimer’s, advocating for a holistic and personalized approach to treatment, which includes both drug discovery and lifestyle interventions to promote brain health.

Beyond his work with ADDF, Dr. Fillit has held numerous leadership roles in academia, biotechnology, and the pharmaceutical industry. He has been involved in the development of several innovative drugs for Alzheimer’s and continues to serve on advisory boards and panels, shaping the direction of Alzheimer’s research and public health policy. His contributions have earned him widespread recognition, including awards for his dedication to advancing geriatric medicine and Alzheimer’s research.

Dr. Fillit is also a passionate advocate for educating both the medical community and the public about aging and neurodegenerative diseases. He is a frequent speaker at national and international conferences, where he discusses the latest advances in Alzheimer's drug discovery and the importance of fostering collaboration between researchers, clinicians, and industry leaders to combat the global Alzheimer's epidemic.

Alzheimer's Disease Alzheimers, Health, Healthcare, Pharmaceutical,